Allmed Medical Products Co., Ltd. Class A

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A carries a market capitalization of 5.63B, placing it among publicly traded companies globally. Its enterprise value stands at 6.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A has 633.27M shares outstanding.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 26.51. The price-to-sales ratio is 1.43, and the price-to-book ratio stands at 1.52.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A trades at an EV/EBITDA multiple of 24.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.41B versus a market cap of 5.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.80, indicating elevated leverage, while an interest coverage ratio of 12.70 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Allmed Medical Products Co., Ltd. Class A posted a return on equity (ROE) of 5.74, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.00 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.52, useful for judging operating efficiency across full business cycles. The company generates approximately 653,813.82 in revenue per employee across its workforce of 5,859.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.58 indicates how many times Allmed Medical Products Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Allmed Medical Products Co., Ltd. Class A recorded 32.22M in income tax expense. That works out to an effective tax rate of 12.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 256.29M, leaving 206.93M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Allmed Medical Products Co., Ltd. Class A's stock has declined approximately 17.52% over the past 52 weeks. The 50-day moving average sits at 8.89, while the 200-day moving average is 10.46.

Over the twelve months ended June 30, 2026, Allmed Medical Products Co., Ltd. Class A generated 3.83B in revenue and converted that into 206.93M in net income, yielding earnings per share of 0.36. EBITDA reached 266.71M, while operating income came in at 611.93M.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A holds 471.75M in cash and equivalents against 1.22B in total debt, resulting in a net debt position of 804.49M. Total book value stands at 3.69B, with working capital of 844.15M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Allmed Medical Products Co., Ltd. Class A posted a gross margin of 29.01, reflecting its pricing power and cost economics. The operating margin of 15.97 and net profit margin of 5.40 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Allmed Medical Products Co., Ltd. Class A paid dividends of 0.23 per share. The dividend payout ratio of 58.78 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.46, meaning Allmed Medical Products Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Allmed Medical Products Co., Ltd. Class A's most recent stock split took place on June 5, 2020 with a 2:3 split ratio.

As of June 30, 2026, Allmed Medical Products Co., Ltd. Class A has an Altman Z-Score of 3.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.